Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology

Prioritizing Safety: Understanding and Reducing SUDEP Risk

At a Glance

The most effective way to reduce SUDEP risk in Dravet syndrome is by decreasing the frequency of convulsive seizures through optimized treatments. Layered safety measures, including nighttime monitoring, having rescue medications ready, and using the recovery position after seizures, provide vital protection.

Talking about SUDEP (Sudden Unexpected Death in Epilepsy) is perhaps the most difficult part of a Dravet syndrome diagnosis. It is a topic that carries immense weight, but understanding the risks allows you to take concrete, actionable steps to protect your child. While the risk in Dravet syndrome is higher than in many other forms of epilepsy, modern treatments and monitoring strategies are actively helping to lower these numbers [1][2].

Understanding the Risk in Dravet Syndrome

SUDEP refers to the sudden death of a person with epilepsy that is not caused by injury, drowning, or a known illness [2]. In the general epilepsy population, the risk is about 1 in 1,000 people per year; however, in Dravet syndrome, historical data has estimated this risk at approximately 9 in 1,000 per year [3][2].

Researchers believe several factors contribute to this increased risk:

  • Seizure Severity: Frequent and prolonged convulsive seizures are the primary risk factor [4][5].
  • Biological Vulnerability: The SCN1A mutation affects how the heart and the brain’s breathing centers communicate during a seizure [6][7].
  • Ictal Arrhythmias: Some children may experience irregular heart rhythms or breathing pauses (apnea) during a seizure [6][8].

Actionable Safety Measures

While no single tool can eliminate the risk entirely, a “layered” safety approach is currently the best way to protect your child.

1. Optimization of Treatment

The most effective way to reduce SUDEP risk is to reduce the number of convulsive seizures [5]. Recent studies have shown that newer treatments like fenfluramine may significantly lower SUDEP rates, with some data suggesting a reduction from the historical 9.3 per 1,000 down to as low as 1.7 per 1,000 person-years [1][9].

2. Nighttime Supervision and Monitoring

Most SUDEP events occur during sleep, often when a seizure is unwitnessed [10][11].

  • Supervision: Having a caregiver nearby or using high-quality audio/video monitors can allow for faster intervention [12][13].
  • Monitoring Devices: Wearable devices that track heart rate, oxygen levels (pulse oximetry), or convulsive movements can alert you to a seizure in real-time [14][15]. While these devices are not “SUDEP-prevention” machines, they are vital for ensuring a caregiver is present to help [12].
  • Repositioning: After a seizure, it is critical to ensure your child is not lying face-down (prone). Turning them onto their side (the recovery position) helps keep their airway clear [13][11].

3. Emergency “Rescue” Protocols

Prolonged seizures, or status epilepticus, are a major medical emergency in Dravet syndrome [16].

  • Rescue Meds: Always have your prescribed rescue medication (such as midazolam or diazepam) available and ensure all caregivers know how to use it [17][18].
  • The “No-Go” List: Ensure your Seizure Action Plan clearly states that emergency responders should NOT use sodium channel blockers like fosphenytoin or phenytoin [16][19]. In an emergency, you may be too panicked to successfully argue with paramedics following standard protocols. To enforce this, have your epileptologist sign a formal Seizure Action Plan to hand directly to responders, and ensure your child wears a clear medical alert bracelet explicitly stating the medication contraindications.

The Role of the Caregiver

You are your child’s most important safety monitor. By maintaining a strict medication schedule, avoiding known triggers like overheating, and using monitoring technology, you are creating a safer environment [20][21]. Having an honest, open conversation with your pediatric epileptologist about SUDEP is not just okay—it is a vital part of your child’s care plan [22]. Identifying your child’s specific risks allows you to build the most effective safety net possible.

Common questions in this guide

Why is the risk of SUDEP higher in Dravet syndrome?
Children with Dravet syndrome face a higher risk due to frequent and prolonged convulsive seizures. Additionally, the underlying SCN1A genetic mutation can affect how the heart and brain's breathing centers communicate during a seizure event.
How can I reduce the risk of SUDEP for my child?
The best way to lower SUDEP risk is to work with your doctor to reduce the number of convulsive seizures using optimized medications like fenfluramine. Using nighttime monitors and having a caregiver nearby during sleep also drastically improves safety.
What monitoring devices are best for detecting nighttime seizures?
Wearable devices that track heart rate, oxygen levels, or convulsive movements are excellent for nocturnal monitoring. While they do not prevent SUDEP on their own, they immediately alert a caregiver so they can intervene and administer first aid.
What should emergency responders know about treating my child's seizures?
Your Seizure Action Plan must clearly state that emergency responders should not use sodium channel blockers like fosphenytoin. Always hand them a doctor-signed plan and ensure your child wears a medical alert bracelet detailing these medication contraindications.
How should I position my child after a seizure?
After a seizure, you should carefully turn your child onto their side into the recovery position. This prevents them from lying face-down, keeps their airway clear, and significantly reduces breathing risks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the most current data on SUDEP risk for children with my child's specific SCN1A mutation?
  2. 2.Which nocturnal monitoring device (movement, heart rate, or pulse oximetry) do you recommend for our home setup?
  3. 3.Can we review our Seizure Action Plan to ensure it explicitly warns emergency responders NOT to use fosphenytoin or other sodium channel blockers?
  4. 4.How can we best manage 'ictal arrhythmias' if they were to occur during a seizure?
  5. 5.Are there any specific sleep positions or bedding you recommend to reduce respiratory risks during a seizure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome.

    Cross JH, Galer BS, Gil-Nagel A, et al.

    Seizure 2021; (93()):154-159 doi:10.1016/j.seizure.2021.10.024.

    PMID: 34768178
  2. 2

    Mortality in Dravet syndrome.

    Cooper MS, Mcintosh A, Crompton DE, et al.

    Epilepsy research 2016; (128()):43-47 doi:10.1016/j.eplepsyres.2016.10.006.

    PMID: 27810515
  3. 3

    Sudden unexpected death in epilepsy. A nationwide population-based study.

    Einarsdottir AB, Sveinsson O, Olafsson E

    Epilepsia 2019; (60(11)):2174-2181 doi:10.1111/epi.16349.

    PMID: 31571204
  4. 4

    Mortality in Dravet syndrome: A review.

    Shmuely S, Sisodiya SM, Gunning WB, et al.

    Epilepsy & behavior : E&B 2016; (64(Pt A)):69-74 doi:10.1016/j.yebeh.2016.09.007.

    PMID: 27732919
  5. 5

    Spotlight on mechanism of sudden unexpected death in epilepsy in Dravet syndrome.

    Shao W, Liu L, Gu J, et al.

    Translational psychiatry 2025; (15(1)):84 doi:10.1038/s41398-025-03304-8.

    PMID: 40097380
  6. 6

    Cardiac arrhythmias in Dravet syndrome: an observational multicenter study.

    Shmuely S, Surges R, Helling RM, et al.

    Annals of clinical and translational neurology 2020; (7(4)):462-473 doi:10.1002/acn3.51017.

    PMID: 32207228
  7. 7

    Electroencephalography characteristics related to risk of sudden unexpected death in epilepsy in patients with Dravet syndrome.

    Kim JY, Shin J, Kim L, Kim SH

    Frontiers in neurology 2023; (14()):1222721 doi:10.3389/fneur.2023.1222721.

    PMID: 37745659
  8. 8

    Oxygen for seizures, more questions than answers: A scoping review.

    Smith AN, Abraham J, Shankar R

    Acta neurologica Scandinavica 2021; (144(6)):719-729 doi:10.1111/ane.13508.

    PMID: 34309004
  9. 9

    Enhancing the action of serotonin by three different mechanisms prevents spontaneous seizure-induced mortality in Dravet mice.

    Guo J, Min D, Farrell EK, et al.

    Epilepsia 2024; (65(6)):1791-1800 doi:10.1111/epi.17966.

    PMID: 38593237
  10. 10

    A population-based post mortem study of sudden unexpected death in epilepsy.

    Clark D, Riney K

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (23()):58-62 doi:10.1016/j.jocn.2015.04.027.

    PMID: 26387918
  11. 11

    Nocturnal supervision and SUDEP risk at different epilepsy care settings.

    van der Lende M, Hesdorffer DC, Sander JW, Thijs RD

    Neurology 2018; (91(16)):e1508-e1518 doi:10.1212/WNL.0000000000006356.

    PMID: 30242018
  12. 12

    Risk of SUDEP during infancy.

    Trivisano M, Muccioli L, Ferretti A, et al.

    Epilepsy & behavior : E&B 2022; (131(Pt B)):107896 doi:10.1016/j.yebeh.2021.107896.

    PMID: 33741238
  13. 13

    The probability of sudden unexpected death in epilepsy given postictal prone position.

    Esmaeili B, Dworetzky BA, Glynn RJ, Lee JW

    Epilepsy & behavior : E&B 2021; (116()):107775 doi:10.1016/j.yebeh.2021.107775.

    PMID: 33571837
  14. 14

    Sudden Unexpected Death in Epilepsy (SUDEP): A Review of Risk Factors and Possible Interventions in Children.

    Wicker E, Cole JW

    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2021; (26(6)):556-564 doi:10.5863/1551-6776-26.6.556.

    PMID: 34421404
  15. 15

    Multimodal nocturnal seizure detection in children with epilepsy: A prospective, multicenter, long-term, in-home trial.

    van Westrhenen A, Lazeron RHC, van Dijk JP, et al.

    Epilepsia 2023; (64(8)):2137-2152 doi:10.1111/epi.17654.

    PMID: 37195144
  16. 16

    Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

    Ziobro J, Eschbach K, Sullivan JE, Knupp KG

    Current treatment options in neurology 2018; (20(12)):52 doi:10.1007/s11940-018-0537-y.

    PMID: 30315507
  17. 17

    Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.

    Cruickshank M, Imamura M, Booth C, et al.

    Health technology assessment (Winchester, England) 2022; (26(20)):1-76 doi:10.3310/RSVK2062.

    PMID: 35333156
  18. 18

    Status Epilepticus.

    Siegel CR, Khoujah D

    Emergency medicine clinics of North America 2026; (44(1)):187-202 doi:10.1016/j.emc.2025.08.011.

    PMID: 41260851
  19. 19

    Dravet Syndrome: Diagnosis and Long-Term Course.

    Connolly MB

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016; (43 Suppl 3()):S3-8 doi:10.1017/cjn.2016.243.

    PMID: 27264139
  20. 20

    Diagnosis, epilepsy treatment and supports for neurodevelopment in children with Dravet Syndrome: Caregiver reported experiences and needs.

    Soto Jansson J, Bjurulf B, Dellenmark Blom M, et al.

    Epilepsy & behavior : E&B 2024; (151()):109603 doi:10.1016/j.yebeh.2023.109603.

    PMID: 38168600
  21. 21

    Parental experiences and perspectives on the value of seizure detection while caring for a child with epilepsy: A qualitative study.

    van Westrhenen A, de Lange WFM, Hagebeuk EEO, et al.

    Epilepsy & behavior : E&B 2021; (124()):108323 doi:10.1016/j.yebeh.2021.108323.

    PMID: 34598099
  22. 22

    The influence of risk factors, biomarkers and care settings on SUDEP counseling.

    Valdrighi A, Laze J, Farooque P, et al.

    Epilepsy & behavior : E&B 2024; (156()):109845 doi:10.1016/j.yebeh.2024.109845.

    PMID: 38788665

This page provides educational information about SUDEP and seizure safety for Dravet syndrome. It does not replace professional medical advice; always consult your epileptologist to develop a personalized Seizure Action Plan.

Get notified when new evidence is published on Dravet syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.